Financials data is unavailable for this security.
View more
Year on year Boston Scientific Corp grew revenues 12.29% from 12.68bn to 14.24bn while net income improved 128.22% from 698.00m to 1.59bn.
Gross margin | 69.09% |
---|---|
Net profit margin | 11.24% |
Operating margin | 17.01% |
Return on assets | 4.96% |
---|---|
Return on equity | 9.06% |
Return on investment | 5.85% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Boston Scientific Corp fell by 71.00m. However, the company earned 2.50bn from its operations for a Cash Flow Margin of 17.58%. In addition the company generated 5.00m cash from financing while 2.57bn was spent on investing.
Cash flow per share | 2.04 |
---|---|
Price/Cash flow per share | 43.03 |
Book value per share | 14.05 |
---|---|
Tangible book value per share | -0.0536 |
More ▼
Balance sheet in USDView more
Current ratio | 1.48 |
---|---|
Quick ratio | 1.02 |
Total debt/total equity | 0.5256 |
---|---|
Total debt/total capital | 0.3419 |
More ▼
Growth rates in USD
SmartText is unavailable
EPS growth(5 years) | -1.29 |
---|---|
EPS (TTM) vs TTM 1 year ago | 48.30 |